Metronom Health CEO Michele Lussie shares insights and details from the company's CGM devide
Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and commercialization of transformative glucose monitoring products, today announced the company plans to participate in the upcoming Canaccord Genuity Growth Conference in Boston, MA, to present Thursday, August 9, 2018 at 1:30pm ET.
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pump available in the United States, today reported its financial results for the quarter ended June 30, 2018. In comparing the second quarter of 2018 to the same period of 2017: Pump shipments increased 59 percent to 5,447 pumps from 3,427 pumps, Sales increased 60 percent to $34.1 million from $21.3 million, Operating margin improved to negative 41 percent from negative 89 percent.
DarioHealth Corp. (NASDAQ: DRIO), a leading global digital health company with mobile health and big data solutions, today announced that it will release its second quarter 2018 results on Thursday, August 9th and host a conference call the same morning at 9:00am EDT.
Patients used the Wellthy Therapeutics' Type II Diabetes patient app for 16 weeks, while paramedical staff used the Wellthy Therapeutics' Type II Diabetes dashboard to monitor and intervene. The result was twofold: an improvement in health behaviours and health outcomes for patients, and a large addition to real world clinical data that helped healthcare stakeholders make better decisions.
#mobile app
#dtx
Nemaura Medical Inc. (NASDAQ: NMRD), a medical technology company developing sugarBEAT® announced it has initiated the first of a number of planned studies in support of a submission to the U.S Food & Drug Administration for approval of its sugarBEAT® product, and further announced positive interim results from the home-use portion of this initial study. The results analysed 121 matched pair points between the BGM and sugarBEAT®, and indicated 84.3% of the data points had an overall MARD (Mean absolute relative deviation) of 10.63%, and an overall nominal MARD of 16.3% (compared with 14.8%, 16.3% and 18% for Eversense, Dexcom G5 and Abbott Libre Pro respectively*).
#cgm
Voluntis, a digital biotech specialized in digital therapeutics, announces the launch its Theraxium Oncology offer, a breakthrough technology that leverages digital therapeutics to empower patients so they can self-manage their symptoms, experienced when receiving cancer treatments, in coordination with care teams.
#dtx
Evidation Health, a health and measurement company that helps life sciences and health care companies understand how everyday behaviors and health interact, announced today that it has raised $30 million in Series C funding. Already, the platform is being used to invent new ways to measure health across diabetes and cognitive decline. This complements the work that the company is performing with partners across multiple therapeutic areas ranging from cardiovascular disease to chronic pain, rheumatoid arthritis, migraine, depression and anxiety, fatigue, heart failure, and asthma — to name a few.
Healthy Interactions, a population health company that offers both digital and in-person programs for chronic disease management and education, and Merck have launched a diabetes management and engagement platform designed to support in-person counseling programs.
#product & service
#coaching
#telehealth
Evidation Health is teaming up with Tidepool to launch a connected device-powered study of nocturnal hypoglycemic events in people with Type 1 diabetes. The research is novel in that connected devices — including Dexcom continuous glucose monitors, an Emfit sleep monitor, and a WHOOP activity tracker — will allow researchers to access data about overnight low blood sugar events that previously hasn't been available. Participants will be recruited online through Evidation's Achievement platform, and they'll also complete daily brain games, adding another source of data.
#product & service